Article Text

Download PDFPDF

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
  1. E. A. Calhoun*,,
  2. E. E. Welshman*,,
  3. C.-H. Chang,
  4. J. R. Lurain,
  5. D. A. Fishman,
  6. T. L. Hunt** and
  7. D. Cella,§
  1. * Department of Urology, Northwestern University Medical School, Chicago, Illinois
  2. Institute for Health Services and Health Policy Studies, Northwestern University Medical School, Chicago, Illinois
  3. Department of Obstetrics and Gynecology, Northwestern University Medical School, Chicago, Illinois
  4. § Department of Psychiatry, Northwestern University Medical School, Chicago, Illinois
  5. ** Department of Pfizer Corporation, Peapack, New Jersey
  1. Address correspondence and reprint requests to: Elizabeth Calhoun, Northwestern University, 339 E. Chicago Avenue #802, Chicago, IL 60611. E-mail: e-calhoun{at}northwestern.edu.

Abstract

The purpose of this study was to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) questionnaire. The FACT/GOG-Ntx is the FACT-G plus an eleven-item subscale (Ntx subscale) that evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. Two groups of women with ovarian cancer completed the FACT/GOG-Ntx: one group with known neurotoxicities and one group of chemotherapy-naive women newly diagnosed with ovarian cancer. Levels of patient neuropathy, severity of toxicity, and patient quality of life from diagnosis of ovarian cancer to 12 months post-diagnosis were assessed. The Ntx subscale significantly differentiated the two groups at baseline and 3- and 6-month follow-ups, demonstrating significantly fewer problems among chemotherapy-naive patients than among patients with known neuropathy. The FACT/GOG-Ntx is a reliable and valid instrument for assessing the impact of neuropathy on health-related quality of life. The Ntx subscale demonstrated sensitivity to meaningful clinical distinctions and change over time.

  • neurotoxicity
  • patient-reported outcomes
  • peripheral neuropathy
  • quality of life

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.